Redeye comments on Gasporox Q1'23 report which beat expectations across the board. Gasporox is executing on the long-term opportunity, expanding its geographic reach and product portfolio. We make a slight negative revision to our Q2'23 estimate on the back of the strong Q1'23 report. We reiterate our base case of SEK25.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Gasporox - Best quarter yet

© Modular Finance, source Nordic Press Releases